Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: QLT PhotoTherapeutics

This article was originally published in The Gray Sheet

Executive Summary

QLT PhotoTherapeutics: Launch of the firm's Photofrin laser light-activated cancer drug for advanced esophageal cancer by U.S. marketing partner Sanofi Winthrop is scheduled for September pending FDA's sign off on promotional materials, states Julia Levy, president and CEO, at an Aug. 13 session of the Medical Investments Northwest conference in Seattle. Laserscope and Coherent laser systems approved for performing photodynamic therapy in December 1995 in conjunction with the drug will be marketed separately by the two firms ("The Gray Sheet" Jan. 15, p. 6). Pivotal clinical trials with Photofrin will begin before year end for treating Barrett's esophagus, a pre-cancerous condition. A supplementary new drug application will be filed with FDA for treatment of lung cancer "before the end of the year," Levy said...

You may also be interested in...

Oxford/AstraZeneca Vaccine Shows 70% Efficacy As Company Prepares Approval Filings

Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.

EBITDA Margin Of 33% Not Sustainable, Krka Underlines

Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.

Pandemic Spotlights Tensions Between Profit And Philanthropy

The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts